The neuroscience and urology franchise reported revenues of $380.4 million in 3Q17, compared with $330.7 million in 3Q16. This growth was driven by the increased sales of Botox therapeutic products and Rapaflo. Notably, the SPDR S&P Pharmaceuticals ETF (XPH) has 3.3% of its total investments …

Link to Full Article: Read Here

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!